From Science to Commercial Value: What Biotech Founders Get Wrong About Positioning

Most biotech innovations do not fail because the science is weak. They fail because the commercial narrative is unclear, untargeted or unconvincing. Scientist-founders often arrive at investor meetings with technical depth and limited commercial framing. This is the positioning problem.

Three positioning mistakes scientist-founders make

Mistake 1: Confusing features with value
A feature is what your technology does. Value is what changes for the person who uses it. Investors, partners and customers do not buy features. They buy outcomes. A clear value proposition starts from the outcome and works backward to the technology.

Mistake 2: Speaking to too many audiences at once
The strongest positioning is not the broadest. It is the most specific. Choosing a primary use case does not mean abandoning the others. It means deciding which application will generate the first commercial traction.

Mistake 3: Mistaking validation for traction
Scientific validation tells the world your science is credible. Commercial traction is evidence that someone is willing to commit resources to using your product. Investors learn quickly to tell them apart.

What investor-ready actually means

An investor-ready pitch is a coherent argument that survives questioning. A few signals it is approaching readiness: the value proposition is stated in one sentence without jargon, the first commercial application is specific, competitive positioning is honest, and the team can articulate the next 12 to 18 months of commercial milestones, not just scientific ones.